PT - JOURNAL ARTICLE AU - Long T. Nguyen AU - Nicolas C. Macaluso AU - Piyush K. Jain TI - A Combinatorial Approach towards Adaptability of 22 Functional Cas12a Orthologs for Nucleic Acid Detection in Clinical Samples AID - 10.1101/2021.07.21.21260653 DP - 2021 Jan 01 TA - medRxiv PG - 2021.07.21.21260653 4099 - http://medrxiv.org/content/early/2021/07/22/2021.07.21.21260653.short 4100 - http://medrxiv.org/content/early/2021/07/22/2021.07.21.21260653.full AB - Reliable, efficient, and cheap detection of infectious diseases, especially in the wake of the SARS-CoV-2 pandemic, is of increasing importance. CRISPR/Cas systems have the capabilities to be optimized for this purpose. There is a broad diversity among Cas12a nucleases with immense detection capability, but only a few have been purified and studied biochemically. Here we present the investigation of 22 Cas12a orthologs, with a focus on their cis- and trans-cleavage activity, and thermal stability in combination with non-canonical crRNAs. We noticed that some non-canonical crRNA:Cas12a effector complexes outperformed its corresponding wild-type crRNA:Cas12a complex in trans-cleavage assays. In particular, TsCas12a, ErCas12a, and ArCas12a showed an increase in thermal stability in binary complex compared to its wild-type structure and apo form. Moreover, Cas12a was observed to have the ability to recruit segments of truncated crRNAs providing insights into crRNA:Cas12a catalytic complex with potential for further applications. We also discovered that ErCas12a, BsCas12a, BoCas12a, and TsCas12a possess robust trans-cleavage activity with a shorter PAM sequence requirement. Finally, we applied these effector complexes to discriminately detect SARS-CoV-2 and its B.1.1.7 lineage in clinical nasopharyngeal swabs, saliva samples, and tracheal aspirates. Our findings further expand the toolbox for next-generation CRISPR-based diagnostics.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by funds from the University of Florida (UF), the UF Herbert Wertheim College of Engineering, Florida Breast Cancer Foundation (AGR00018466), and the United States-India Science & Technology Endowment Fund (USISTEF/COVID-I/247/2020).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was performed under the UF IRB protocol IRB202000781.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData and materials availability: All data associated with this study are in the main text and the Supplementary Materials. The expression plasmids will be soon deposited to Addgene after obtaining the required permissions.